Holen Sie sich die Stockscreener-App
157.20
2.36%
3.63
Handel nachbörslich:
157.19
-0.010
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$153.57
Offen:
$154.24
24-Stunden-Volumen:
4.67M
Relative Volume:
0.74
Marktkapitalisierung:
$194.92B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
21.39
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-0.11%
1M Leistung:
+2.97%
6M Leistung:
+18.28%
1J Leistung:
+29.43%
1-Tages-Spanne:
$153.00
$157.42
1-Wochen-Bereich:
$151.71
$157.57
52-Wochen-Spanne:
$114.02
$160.51
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
157.20 | 194.92B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,306.74 | 1.16T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.74 | 645.23B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
284.89 | 503.43B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.29 | 363.39B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.30 | 297.08B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-07-06 | Hochstufung | HSBC Securities | Hold → Buy |
| 2026-05-20 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences stock may move 4.6% on Oct. 29 earnings release - Investing.com
Gilead to Present New Data on Treatment Response and Long-Term Ma - The National Law Review
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026 - Business Wire
BioNTech, Gilead to test drug combination in advanced breast cancer trial - Reuters
Gilead Sciences, Inc. (GILD) stock price, news, quote and historyYahoo Finance - Yahoo Finance Singapore
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Gilead Sciences, Inc. $GILD Stock Sold by Crossmark Global Holdings Inc. - MarketBeat
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Gilead Sciences, Inc. (GILD) Options Chain - Yahoo! Finance Canada
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push - BioSpace
BofA raises Gilead Sciences stock price target on positive trial data - Investing.com
15,240 Gilead Sciences, Inc. $GILD Shares Bought by CWA Asset Management Group LLC - MarketBeat
How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals - Yahoo Finance
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success - Benzinga
Gilead Sciences, Inc. (GILD) stock price, news, quote and history - Yahoo Finance UK
What Has Changed About Owning Gilead Stock? - Trefis
Gilead Sciences (GILD) Reports Promising Mid-Stage Trial Results for Emvistegrast in Ulcerative Colitis - GuruFocus
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy - Zacks Investment Research
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy - Yahoo Finance
Gilead's pill succeeds in mid-stage bowel disease trial - Reuters
Gilead bowel drug hits mid-stage trial win (GILD:NASDAQ) - Seeking Alpha
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 - BioSpace
Gilead to present HIV and antiviral research at IDWeek 2026 - Investing.com
Gilead Sciences, Inc. (GISD.XC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gilead Sciences, Inc. (GISD.XC) stock price, news, quote and history - Yahoo Finance UK
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 - Business Wire
43 ETFs Add to Gilead Sciences (GILD) on Thursday - Yahoo Finance
Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds - STAT
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? - The Motley Fool
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc. - MarketBeat
Under a trading plan, Gilead Sciences (GILD) CFO sells 3,000 shares at $156.22 each. - Stock Titan
Gilead Sciences, Inc. $GILD Shares Sold by Curated Wealth Partners LLC - MarketBeat
Could Gilead Sciences (NASDAQ:GILD) Be in Focus After Wall Street’s Latest Rotation? - Kalkine Media
Gilead Sciences, Inc. $GILD Stock Sold by Assenagon Asset Management S.A. - MarketBeat
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Yahoo Finance
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Zacks Investment Research
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Business Wire
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research
Gilead Sciences Inc Stock (GILD) Moved Up by 3.67% on Oct 15: Key Drivers Unveiled - TradingKey
Gilead Sciences (NASDAQ:GILD) Hits New 52-Week HighHere's What Happened - MarketBeat
Gilead Sciences stock hits all-time high at 157.32 USD - Investing.com
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Oct 15 '26 |
Sale |
156.22 |
3,000 |
468,660 |
113,684 |
| JOHANNA MERCIER | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| ANDREW DICKINSON | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Oct 01 '26 |
Sale |
147.90 |
15,000 |
2,218,508 |
566,683 |
| ANDREW DICKINSON | Officer |
Sep 15 '26 |
Proposed Sale |
145.29 |
3,000 |
435,870 |
0 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
| Dickinson Andrew D | Chief Financial Officer |
Sep 15 '26 |
Sale |
145.29 |
3,000 |
435,870 |
164,096 |
| JOHANNA MERCIER | Officer |
Sep 15 '26 |
Proposed Sale |
144.22 |
3,000 |
432,646 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Sep 01 '26 |
Sale |
148.64 |
15,000 |
2,229,592 |
577,133 |
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Sale |
148.62 |
18,000 |
2,675,220 |
12,894 |
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):